Ortho Dermatologics Announces U.S. FDA Filing Acceptance For Acne Treatment In Lotion Form

Ortho Dermatologics (NYSE: VRX) announced the FDA has accepted the New Drug Application for IDP-121. Altreno will be the first tretinoin product in lotion form rather than a gel or cream.

“More than 4 million patients make appointments with dermatologists each year for acne. It is our goal to be the go-to resource for doctors and patients for all dermatological conditions, and if approved, ALTRENO will be a valuable addition to the Ortho Dermatologics portfolio,” said Joseph C. Papa, chairman and CEO, Valeant.
Acne, also known as acne vulgaris, is the most common skin disease in the United States, and as many as 50 million people in the United States may have the disease

Click here to read the full press release.